GlassScriptPhysician profile
Perry G Carlos
NPI 1801873443
$12,740.85
in general payments reported to CMS, 2019-2025
53 companies · $1,522 in 2025
The $1,522 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,703 · 2020: $1,789 · 2021: $2,464 · 2022: $1,708 · 2023: $1,856 · 2024: $1,697 · 2025: $1,522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,075.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,271.01 | 2019-2025 | |
| Novo Nordisk INC | $1,208.34 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $967.70 | 2019-2025 | Ubrelvy, Viberzi, Linzess |
| Astrazeneca Pharmaceuticals LP | $909.20 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $843.99 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $808.85 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $743.85 | 2019-2024 | Shingrix, Arexvy, Bexsero |
| Amgen INC. | $707.43 | 2019-2025 | Otezla, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $696.24 | 2019-2024 | Capvaxive, Steglatro, Gardasil 9 |
| Astellas Pharma US INC | $566.69 | 2019-2023 | Myrbetriq |
| Amarin Pharma, INC. | $508.02 | 2019-2022 | |
| Antares Pharma, INC. | $356.31 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Janssen Pharmaceuticals, INC | $340.25 | 2020-2025 | Spravato, Xarelto |
| Phathom Pharmaceuticals, INC. | $264.21 | 2024-2025 | Voquezna |
| Abbott Laboratories | $206.94 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Perry Carlos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.